Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, in a post-CDK inhibitor setting, compared with standard-of-care endocrine therapy plus everolimus1The giredestrant combination was well tolerated; no new safety signals were observed including no photopsia1 Overall survival data were immature, but a clear positive trend was seen in both the ITT and ESR1-mutated populations1 If approved, giredestrant plus everolimus ...